Compare BioNTech SE - ADR (BNTX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Charles Schwab Corporation Common Stock — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Charles Schwab Corporation Common Stock trades at $109.34 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 8× BioNTech SE - ADR's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | SCHW | |
|---|---|---|
Market Cap | $23.31B | $186.25B |
Sector | Health | Financials |
52-Week High | $119.34 | $108.02 |
52-Week Low | $83.89 | $85.35 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Charles Schwab (SCHW) trades at $109.28, up 1.19% today, near its all-time high of $109.05 (Zacks Investment Research, 2026-08-07). The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92 billion in 2025, with net income margin expanding to 37%, while analyst consensus is bullish with a $122.33 price target. Recent news highlights insider selling and ongoing litigation, but institutional acquisitions signal confidence.
Outlook remains positive driven by earnings growth and market share gains, but risks include regulatory scrutiny from lawsuits (Business Wire, 2026-08-10) and interest rate sensitivity. The stock offers upside to consensus targets, though overbought conditions suggest potential near-term volatility. Investors should weigh robust fundamentals against macroeconomic and legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
